Scholar Rock Holding Corp (SRRK) 今日盘中大幅上涨10.59%，引发市场广泛关注。
消息面上，公司最新披露的第二季度财报显示，每股净亏损为0.84美元，较去年同期的每股0.98美元明显收窄，业绩改善趋势显著。与此同时，公司旗下脊髓性肌萎缩症(SMA)药物apitegromab的上市申请正在接受美国食品药品监督管理局(FDA)审查，且进展顺利。公司目前拥有两家灌装和包装工厂，这意味着在9月30日前将有两条独立的审批路径，经纪公司Truist亦表示，第二家灌装/包装基地应有助于该药物在短期内获得美国批准。
此外，公司已为apitegromab的商业化做好充分准备，一旦获得FDA批准即可在美国市场推出，且商业化所需供应充足。截至2026年6月30日，公司持有现金、现金等价物及有价证券共计4.921亿美元，为后续运营及商业化提供了坚实的资金保障，进一步增强了市场信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.